Sequence Variation in the E2-Binding Domain of HPV16 and Biological Function Evaluation in Tunisian Cervical Cancers

Table 2

Sequence variations and amino acid substitutions of HPV16 E2 variants compared to the reference sequence.

Polymorphism					Malignant; (𝑛=9)	Benign; (𝑛=9)
Domain	Nucleotide		Amino acid residue
	Number	Change	Number	Change
Amino terminal; (Transactivation domain)	2860	C>A	35	His>Gln	4	1
	2926	A>G	57	Gln*	6	4
	2938	A>G	61	Thr*	5	3
	3043	C>T	96	Asp*	4	1
	3159	C>A	135	Thr>Lys	2	0
	3161	C>T	136	His>Tyr	3	1
	3182	G>A	143	Ala>Thr	2	0
	3249	G>A	165	Arg>Gln	4	0
	3362	A>G	203	Asn>Asp	2	0
	3377	C>G	208	Pro>Ala	1	0
	3384	T>C	210	Ile>Thr	5	8
	3410	C>T	219	Pro>Ser	7	6
Hinge	3431	G>A	226	Ala>Thr	4	1
	3449	G>A	232	Glu>Lys	3	1
	3516	C>A	254	Thr*	2	1
	3517	T>C	254	Thr>Asn	4	1
Carboxy terminal; (DNA-Binding Domain)	3538	A>C	261	Ser*	4	1
	3566	T>G	271	Phe>Val	2	0
	3684	C>A	310	Thr>Lys	7	2
	3694	T>A	313	Thr*	2	0
	3706	T>C	317	Ser*	4	1
	3778	G>T	341	Trp>Cys	3	0
	3787	C>A	344	Asp>Glu	4	0
	3790	A>T	347	Ile>Phe	3	1
	3805	T>G	350	Val*	2	0

∗No amino acid change.